After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy

Contrasts With Pfizer Safety Concerns

 
• By Andrew McConaghie

CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.

Sarepta Building 2
The latest Phase II readout adds to growing data suggesting Sarepta's gene therapy could prove safe and effective. • Source: Alamy

More from Business

More from Scrip